Chosa

Chosa Oncology (previously RhoVac) is a Danish biotech focused on the development of iCIP, a technology consisting of a cisplatin drug response predictor and a liposomal formulation of conventional cisplatin. iCIP has demonstrated encouraging clinical proof of concept from a Phase IIb study in breast cancer patients and Chosa is now looking for strategic partnerships to progress clinical development of the technology.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: The cost of insecure infrastructure

Have autos hit the brakes too hard?

The investment story needs to be seen

Audiovisual

Latest

BlackRock Greater Europe Investment Trust — BlackRock Greater Europe Investment Trust – equity proposition

Corero Network Security – executive interview

Uncovering Trusts – Baker Steel Resources Trust (BSRT): Capturing value along the mining development curve

About Edison

Corporates

Investors

Careers

Chosa (XSAT: CHOSA)

Latest Insights

CHOSA Oncology – executive interview

Chosa Oncology — Making headway in precision oncology

RhoVac — On the home straight

RhoVac — Phase IIb BRaVac study results in H122

Share Price Chart

Market Data

Sector

Equity Analyst

Key Management

RhoVac — Funded to execute Phase IIb study as planned

RhoVac — Stopping metastasis in its tracks